ArticleScientific reports2019
Berberine improved experimental chronic colitis by regulating interferon-γ- and IL-17A-producing lamina propria CD4
Open access · goldAbstract read
In one paragraph
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- A meta-analysis of berberine combined with brain-gut axis-targeted agents for diarrhoea-predominant irritable bowel syndrome.Frontiers in pharmacology · 2026Pooled it
- Berberine Improved the Therapeutic Efficacy of UC-MSCs for DSS-Induced Colitis via Aerobic Glycolysis.Phytotherapy research : PTR · 2026Article
- Berberine AlleviatesInternational journal of molecular sciences · 2026Article
- Berberine is a key active component underlying the anti-allergic actions of orengedokuto in a murine model of contact hypersensitivity.Journal of natural medicines · 2026Article
- Article
- The potential connection between inflammatory bowel disease and Alzheimer's disease: mechanistic insights and therapeutic implications.Frontiers in immunology · 2026Review
- Berberine Prevents NSAID-Induced Small Intestinal Injury by Protecting Intestinal Barrier and Inhibiting Inflammasome-Associated Activation.Digestive diseases and sciences · 2025Article
- Glaucocalyxin A alleviates ulcerative colitis by inhibiting PI3K/AKT/mTOR signaling.Scientific reports · 2025Article
- Targeting Interferon-Gamma (IFN-γ)-Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and Therapeutic Advances.Mediators of inflammation · 2025Review
- Dihydroberberine alleviates Th17/Treg imbalance in premature ovarian insufficiency mice via inhibiting Rheb/mTOR signaling.Molecular medicine (Cambridge, Mass.) · 2024Article
- Anti-inflammatory potential of aconitine produced by endophytic fungus Acremonium alternatum.World journal of microbiology & biotechnology · 2024Article
- Pharmaceutical Potential of Remedial Plants and Helminths for Treating Inflammatory Bowel Disease.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Protective Application of Chinese Herbal Compounds and Formulae in Intestinal Inflammation in Humans and Animals.Molecules (Basel, Switzerland) · 2023Review
- Research Progress on Natural Small-Molecule Compounds for the Prevention and Treatment of Sepsis.International journal of molecular sciences · 2023Review
- The potential role of plant secondary metabolites on antifungal and immunomodulatory effect.Applied microbiology and biotechnology · 2023Review
- Modulating AHR function offers exciting therapeutic potential in gut immunity and inflammation.Cell & bioscience · 2023Review
- Chinese herbal medicines for treating ulcerative colitis via regulating gut microbiota-intestinal immunity axis.Chinese herbal medicines · 2023Review
- Berberine governs NOTCH3/AKT signaling to enrich lung-resident memory T cells during tuberculosis.PLoS pathogens · 2023Article
- Phillygenin Attenuated Colon Inflammation and Improved Intestinal Mucosal Barrier in DSS-induced Colitis Mice via TLR4/Src Mediated MAPK and NF-κB Signaling Pathways.International journal of molecular sciences · 2023Article
- Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study).Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 2 countries.
Masahiro TakaharaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. mtakahara@cc.okayama-u.ac.jp.
Akinobu TakakiDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Sakiko HiraokaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Takuya AdachiDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Yasuyuki ShimomuraDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Hiroshi MatsushitaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Tien Thi Thuy NguyenDepartment of Animal Applied Microbiology, Okayama University Graduate School of Environmental and Life Science, 1-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan.
Kazuko KoikeDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Airi IkedaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Shiho TakashimaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Yasushi YamasakiDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Toshihiro InokuchiDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Hideaki KinugasaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Yusaku SugiharaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Keita HaradaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Shingo EikawaDepartment of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Hidetoshi MoritaDepartment of Animal Applied Microbiology, Okayama University Graduate School of Environmental and Life Science, 1-1-1 Tsushima-naka, Kita-ku, Okayama, 700-8530, Japan.
Heiichiro UdonoDepartment of Immunology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Hiroyuki OkadaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Okayama University · JPHue University of Agriculture and Forestry · VN
Funding
No grant is acknowledged in the PubMed record.
Abstract
The herbal medicine berberine (BBR) has been recently shown to be an AMP-activated protein kinase (AMPK) productive activator with various properties that induce anti-inflammatory responses. We investigated the effects of BBR on the mechanisms of mucosal CD4
Indexed as
Adenosine TriphosphateAMP-Activated Protein KinasesAnimalsBerberineCD4-Positive T-LymphocytesChronic DiseaseColitisCytokinesEnzyme ActivationGastrointestinal MicrobiomeInflammation MediatorsInterferon-gammaInterleukin-17Mice, Inbred BALB CMice, SCIDMucous MembraneAdenosine TriphosphateAMP-Activated Protein KinasesBerberineCytokinesInflammation MediatorsInterferon-gammaInterleukin-17
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.